Obesity

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

N Engl J MedPublished Randomised controlled trial

Primary result · Mean % change in body weightResult — go to the resultEstimated difference −17.3 percentage points 95% CI −18.1 to −16.6

Authors' conclusion

Cagrilintide-semaglutide provided significant and clinically relevant body-weight reductions in adults with overweight or obesity, as compared with placebo.

Study context

Population
Adults without diabetes with body-mass index (BMI) ≥30, or BMI ≥27 with ≥1 obesity-related complicationrandomized 21:3:3:7
Participants
3,417 adults
Comparison
Cagrilintide-semaglutide vs placebo
  • Cagrilintide-semaglutiden = 2,108
  • Semaglutiden = 302
  • Cagrilintiden = 302
  • Placebon = 705reference
Primary endpoint
Coprimary: relative change in body weight and body-weight reduction ≥5%, cagrilintide-semaglutide vs placebo
Follow-up
Baseline to week 68
Methodological detailsphase 3a, multicenter, double-blind, placebo-controlled, active-controlled
  • Phase 3a
  • Multicenter
  • Double-blind
  • Placebo-controlled
  • Active-controlled

Primary result

Mean % change in body weight

Estimated difference

−17.3 percentage points

95% CI −18.1 to −16.6

P < 0.001

Change by group

Cagrilintide-semaglutide

−20.4%

mean

Placebo

−3.0%

mean

Cagrilintide-semaglutidevs Placebo
estimated difference −17.3 percentage points (95% CI −18.1 to −16.6); P < 0.001

As reported in the abstract

Secondary outcomes

OutcomeP value
Body-weight reductions ≥20%, ≥25% and ≥30% (confirmatory secondary)Cagrilintide-semaglutide vs Placebo · more likely with cagrilintide-semaglutideP < 0.001 for all comparisons

Safety

OutcomeCagrilintide-semaglutidePlacebo
Gastrointestinal adverse events79.6%39.9%

Gastrointestinal adverse events

Mainly transient and mild-to-moderate in severity

Original publication

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. Published 22 June 2025. doi:10.1056/nejmoa2502081

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.